Act Now to Protect Drug Development. As part of the budgeting process, Congress is discussing cutting back the Orphan Drug Tax Credit for pharmaceutical companies. Most of the drugs in sarcoidosis are not FDA-approved for sarcoidosis, but are repurposed from...
What to know about Omicron, the vaccines, the boosters, and staying safe The Omicron variant of the COVID-19 virus is now the dominant variant in the United States and since December cases have been skyrocketing. Vaccines and boosters What makes this variant...
This year, the Foundation for Sarcoidosis Research (FSR) has made incredible progress towards our mission thanks to your support! There have been significant strides made towards accelerating research initiatives and providing resources to patients around the...
#GivingTuesday marks the official start to the charitable giving season! On #GivingTuesday we want to you join us in creating a movement to help stop sarcoidosis. To help celebrate this international day of giving back, we are going to take social media by...
We are proud to announce that they have been selected as an awardee for the Chan Zuckerberg Initiative (CZI) Rare As One Cycle 2 grant which will provide $600,000 to improve diagnostics and increase research in sarcoidosis. This work is part of CZI’s Rare...
FSR is pleased to announce the 2021 Small Research Grant Awardees. As part of our mission, FSR accelerates sarcoidosis research through fellowships, small grants, and large grant programs, and has dedicated over $5M million for worldwide sarcoidosis research since...
The Foundation for Sarcoidosis Research (FSR) is excited to announce the official launch of the first of its kind African American Women & Sarcoidosis National Campaign (AAWS). African American women experience the highest incidence of sarcoidosis in the US as...
Mary McGowan’s Reflections on her First Year Anniversary as FSR’s CEO Over the last year, I learned how resilient the FSR community is, especially during these challenging times of a pandemic. I am so impressed by the passion, dedication and focus...
Health experts urge nations to implement ambitious air pollution reduction policies Health experts and patient representative groups have issued a joint statement urging nations to implement ambitious clean air policies without delay in order to protect health. The...
On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to have supported this clinical trial. The trial demonstrated that ATYR1923 was safe and well-tolerated, 33%...
